On March 17, 2026, the U.S. Court of Appeals for the Ninth Circuit issued a landmark decision in United States ex rel. Adventist Health System of West v. AbbVie Inc.—a ruling poised to significantly reshape how whistleblowers and their attorneys pursue fraud claims related to the federal 340B Drug Pricing Program.
Although the 340B statute itself does not provide a private right of action, the Ninth Circuit held that violations of the program’s pricing rules can support False Claims Act (FCA) liability. The decision reverses a district court dismissal. It also opens the door to a broader wave of FCA actions rooted in 340B overcharge allegations.
This post breaks down the decision, explains why it matters, and outlines what whistleblowers and their attorneys should take from this important development.
Background: The 340B Program and the Alleged Fraud Scheme
The 340B Drug Pricing Program is a U.S. federal program administered by the Health Resources and Services Administration (HRSA). It requires drug manufacturers participating in Medicaid (“covered entities”) to sell outpatient medications at significantly discounted prices to eligible health care organizations, such as safety net hospitals, community health centers, and clinics serving low income or uninsured patients. The program is intended to help “covered entities” stretch limited resources, improve access to medications, and support comprehensive care for vulnerable populations. Savings generated through 340B are not mandated for a specific use. This allows participating providers flexibility to reinvest funds into services like charity care, expanded clinical programs, or reduced medication costs for patients.
While widely credited with strengthening the safety net, the program has also been the subject of ongoing policy debate around transparency, oversight, and the use of savings. In the Adventist case, the relator—a covered entity itself—alleged that multiple pharmaceutical manufacturers knowingly overcharged above the statutory 340B ceiling. As a result, inflated reimbursement claims were submitted to Medicare, Medicaid, and other government healthcare programs. These allegations align with familiar FCA theories. A fraudulent scheme induced government overpayment.
The district court dismissed the action, reasoning that because the Supreme Court in Astra USA, Inc. v. Santa Clara County held there is no private right of action under the 340B statute, Adventist could not proceed under the FCA based on 340B violations. The Ninth Circuit disagreed—and its reasoning is critical for future whistleblower actions.
The Decision: FCA Claims Are Independent of 340B’s Private‑Right‑of‑Action Limits
The Court of Appeals unanimously reversed, holding that the absence of a private right of action under the 340B statute does not bar FCA claims where the government is the injured party. Key points include:
The FCA is “free‑standing and independent” of the 340B statute
The court emphasized that FCA liability does not depend on whether the underlying statutory scheme provides its own right of action. The FCA’s broad mandate allows the government (or relators standing in its shoes) to pursue fraud involving “all types of fraud, without qualification.”
Astra is distinguishable
In Astra, the plaintiff sought to enforce 340B rights on its own behalf. In contrast, Adventist’s FCA suit seeks recovery on behalf of the federal and state governments for allegedly false claims submitted due to inflated prices. Because the relator is not enforcing 340B rights directly—but instead alleging fraud against the government—the Ninth Circuit held the FCA claim can proceed.
Prohibiting FCA actions in this context would undermine congressional intent
The court noted that disallowing such claims would shield fraud from FCA scrutiny in an area where Congress intended wide‑ranging enforcement.
The relator adequately pleaded falsity
The Ninth Circuit rejected manufacturers’ alternative argument that the relator failed to plead falsity. Instead, holding the complaint sufficiently alleged inflated prices and resulting overpayments. The case was remanded for further proceedings.
Why This Decision Matters for Whistleblowers
The Adventist decision has significant ramifications for FCA enforcement—particularly for whistleblowers aware of pricing irregularities or overcharges in the pharmaceutical supply chain.
Expands FCA Pathways for 340B‑Related Fraud
Before this decision, defendants argued that Astra foreclosed FCA actions grounded in 340B violations. The Ninth Circuit has now clarified that FCA claims remain viable, even if the underlying statute lacks a private right of action. Some examples of fraudulent schemes include:
- Overcharging above 340B ceiling prices
- Improper denial of 340B pricing
- Manipulation of pricing data
- Failure to offer mandated “penny pricing”
Strengthens the role of relators in exposing pharmaceutical pricing fraud
Because covered entities directly witness pricing behavior, they are often best positioned to uncover irregularities. The Ninth Circuit’s ruling ensures that whistleblowers can continue bringing FCA actions rooted in 340B misconduct rather than relying solely on HRSA’s administrative processes.
Increases litigation pressure on drug manufacturers
Manufacturers have been scrutinizing ways to reduce their 340B exposure—sometimes through restrictions on contract‑pharmacy arrangements or narrower distribution. The decision is likely to spur:
- More FCA suits alleging overcharges
- Greater risk for manufacturers who push pricing boundaries
- Heightened compliance scrutiny
Encourages more aggressive enforcement by DOJ and relators’ counsel
The FCA’s treble damages and per‑claim penalties create powerful incentives for enforcement. By confirming FCA liability for 340B pricing schemes, the Ninth Circuit has broadened the government’s and relators’ toolbox.
Conclusion
The Ninth Circuit’s ruling in United States ex rel. Adventist Health System of West v. AbbVie Inc. is a major win for whistleblowers and FCA enforcement. By holding that 340B overcharge allegations can proceed under the FCA regardless of the 340B statute’s lack of a private right of action, the court has affirmed the FCA’s broad reach and reinforced the crucial role of relators in uncovering pharmaceutical pricing fraud.
Whistleblower Law Collaborative
Fighting pharmaceutical fraud remains a government priority. We represent whistleblowers nationwide in bringing False Claims Act cases including those alleging pharmaceutical and other types of healthcare fraud. If you have information about possible healthcare fraud, please contact us for a free consultation. We have the expertise and desire to help.